Characterizing Risk Factors and Outcomes in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer Who Do Not Complete, or Who Experience Progression During/Within 42 Days of, Concurrent Chemoradiotherapy: The POSITION Study

Giannis Mountzios, Julius K. Weng, Eleni Zairi, Kristin Hsieh, Pratibha Chander, William Dunlop, Yao Qiao, Alice Wang, Adam Januszewski

Open source

DOI
10.1016/j.cllc.2026.01.005
Published
2026-04
Container
Clinical Lung Cancer
Publisher
Elsevier BV
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.cllc.2026.01.005,
  title = {Characterizing Risk Factors and Outcomes in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer Who Do Not Complete, or Who Experience Progression During/Within 42 Days of, Concurrent Chemoradiotherapy: The POSITION Study},
  author = {Giannis Mountzios and Julius K. Weng and Eleni Zairi and Kristin Hsieh and Pratibha Chander and William Dunlop and Yao Qiao and Alice Wang and Adam Januszewski},
  year = {2026},
  journal = {Clinical Lung Cancer},
  doi = {10.1016/j.cllc.2026.01.005},
  url = {https://doi.org/10.1016/j.cllc.2026.01.005}
}

RIS

TY  - JOUR
TI  - Characterizing Risk Factors and Outcomes in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer Who Do Not Complete, or Who Experience Progression During/Within 42 Days of, Concurrent Chemoradiotherapy: The POSITION Study
AU  - Giannis Mountzios
AU  - Julius K. Weng
AU  - Eleni Zairi
AU  - Kristin Hsieh
AU  - Pratibha Chander
AU  - William Dunlop
AU  - Yao Qiao
AU  - Alice Wang
AU  - Adam Januszewski
PY  - 2026
JO  - Clinical Lung Cancer
DO  - 10.1016/j.cllc.2026.01.005
UR  - https://doi.org/10.1016/j.cllc.2026.01.005
ER  - 

APA

Mountzios, G., Weng, J. K., Zairi, E., Hsieh, K., Chander, P., Dunlop, W., Qiao, Y., Wang, A., & Januszewski, A. (2026). Characterizing Risk Factors and Outcomes in Patients With Unresectable, Stage III Non-Small-Cell Lung Cancer Who Do Not Complete, or Who Experience Progression During/Within 42 Days of, Concurrent Chemoradiotherapy: The POSITION Study. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2026.01.005

Source records